Trials / Not Yet Recruiting
Not Yet RecruitingNCT06672263
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Phase I Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3911 tablets | TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells. |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
- First posted
- 2024-11-04
- Last updated
- 2024-11-04
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06672263. Inclusion in this directory is not an endorsement.